KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 15 years of Accumulated Depreciation & Amortization data on record, last reported at $543.7 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 53.54% year-over-year to $543.7 million; the TTM value through Dec 2025 reached $543.7 million, up 53.54%, while the annual FY2025 figure was $543.7 million, 53.54% up from the prior year.
  • Accumulated Depreciation & Amortization reached $543.7 million in Q4 2025 per REGN's latest filing, up from $354.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $543.7 million in Q4 2025 and bottomed at $303.9 million in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 4 years is $382.6 million, with a median of $341.4 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 7.69% in 2024, then surged 53.54% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $303.9 million in 2022, then rose by 8.19% to $328.8 million in 2023, then increased by 7.69% to $354.1 million in 2024, then surged by 53.54% to $543.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $543.7 million in Q4 2025, $354.1 million in Q4 2024, and $328.8 million in Q4 2023.